Roche is focused on saving people’s eyesight from the leading causes of vision loss. Through our innovation in the scientific discovery of new potential drug targets, personalised healthcare, molecular engineering, biomarkers and continuous drug delivery, we strive to design the right therapies for the right patients.
With a robust pipeline, rationalised in science and informed by insights from people with eye diseases, Roche has the broadest late stage retina pipeline including treatments for neovascular age-related macular degeneration, diabetic macular edema, diabetic retinopathy and retinal vein occlusion. Our early stage pipeline also includes gene therapies and treatments for geographic atrophy and other vision-threatening diseases, including rare and inherited conditions.
For more information on Roche, visit: https://www.roche.com